{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.6","value":"74.5"},{"groupId":"OG001","spread":"13.7","value":"74.5"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.0","value":"74.2"},{"groupId":"OG001","spread":"13.5","value":"70.6"}]}],"title":"12 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.5","value":"70.2"},{"groupId":"OG001","spread":"12.8","value":"73.0"}]}],"title":"24 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.6","value":"69.3"},{"groupId":"OG001","spread":"12.8","value":"72.6"}]}],"title":"36 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.9","value":"72.1"},{"groupId":"OG001","spread":"14.3","value":"73.3"}]}],"title":"52 Weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for ovarian cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). . The FACT-O TOI score is calculated as the sum of the subscale scores if more than 80% of the FACT-O TOI items provide valid answers and all of the component subscales have valid scores. The FACT-O TOI score ranges 0-100 with a large score suggesting better QOL. Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the quality of life endpoint definition","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.\n\nLetrozole: Given PO\n\nPaclitaxel: Given IV\n\nPegylated Liposomal Doxorubicin Hydrochloride: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nTamoxifen: Given PO\n\nTamoxifen Citrate: Given PO\n\nTopotecan: Given IV\n\nTopotecan Hydrochloride: Given IV","id":"OG000","title":"Arm A (Letrozole, Tamoxifen, Paclitaxel, PLD, Topotecan)"},{"description":"Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nQuality-of-Life Assessment: Ancillary studies\n\nTrametinib: Given PO\n\nTrametinib Dimethyl Sulfoxide: Given PO","id":"OG001","title":"Arm B (Trametinib)"}],"paramType":"MEAN","populationDescription":"Patients who provided baseline and ≥ 1 follow-up assessment","reportingStatus":"POSTED","timeFrame":"1. baseline (prior to cycle 1), 12 weeks (prior to cycle 4), 24 weeks (4 weeks post cycle 6), 36 weeks post cycle 1, 52 weeks post cycle 1.","title":"Patients Reported Acute Quality of Life","type":"SECONDARY","unitOfMeasure":"score on a scale"}